Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
Chinese Journal of Biotechnology ; (12): 1041-1050, 2020.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-826872

ABSTRACT

In recent years, the demand of biologics has increased rapidly. Cell culture process with perfusion mode has become more and more popular due to its high productivity, good quality and high efficiency. In this paper, the unique operation and the details of process optimization for perfusion culture mode are discussed by comparing with traditional batch culture process. Meanwhile, the progress and strategies in the development and optimization of perfusion culture process in recent years are summarized to provide reference for the future development of mammalian cell perfusion culture technology.


Subject(s)
Animals , Batch Cell Culture Techniques , Bioreactors , Reference Standards , CHO Cells , Cricetulus , Mammals , Perfusion
2.
Autoimmunity ; 51(5): 210-220, 2018 08.
Article in English | MEDLINE | ID: mdl-30382756

ABSTRACT

Therapeutic efficacy of P277 against type 1 diabetes was extensively investigated and clinically evidenced. Clinical trials Phases I and II concluded promising results, while the data of P277 immunogenicity in Phase III trials represented weak responses that led to abolish medical use. But, a therapeutic performance of P277 cannot be forgotten. So, in order to exploit its therapeutic benefits and improve its immunogenicity, we developed a new analogue VP to optimize therapeutic efficacy and enhancing immunosuppressive modulations. However, new analogue was purified, and then used to immunize diabetic NOD mice to investigate antidiabetic effects through modulation of immunological status. So, DCs immune responses, relative TLRs, MyD88, and NF-Kß1 mRNA expression on DCs and splenocytes under VP effect were tested. Circulating and intracellular cytokines were also evaluated at treated and non-treated mice. Splenic T lymphocytes proliferation (Th1 and Treg cells) were also determined. Results revealed that VP significantly down regulates DCs maturation through TLR2, TLR4, and MyD88 pathways. It also shifts DCs to a tolerogenic polarization through NF-Kß1 pathway that mediates Th1 immunosuppression and enhances iTreg expanding in type1diabetes mice. Meanwhile, we noticed that VP significantly enhances iTreg CD25 + FoxP3+ proliferation. In conclusion, VP showed promising immune potential to modulate immune regulatory responses and shifts DCs to suppress autoreactive Th1 cells which ameliorated immunosuppressive potency in the type1 diabetic mice.


Subject(s)
Autoimmunity/drug effects , Chaperonin 60/pharmacology , Diabetes Mellitus, Type 1/drug therapy , Immune Tolerance/drug effects , Immunosuppressive Agents/pharmacology , Peptide Fragments/pharmacology , Animals , Antibody-Dependent Cell Cytotoxicity/drug effects , Cell Communication/immunology , Chaperonin 60/genetics , Chaperonin 60/immunology , Chaperonin 60/therapeutic use , Dendritic Cells/drug effects , Dendritic Cells/immunology , Diabetes Mellitus, Type 1/immunology , Disease Models, Animal , Epitopes, B-Lymphocyte/genetics , Female , Humans , Immunosuppressive Agents/therapeutic use , Lymphocyte Activation/drug effects , Mice , Mice, Inbred BALB C , Mice, Inbred NOD , Mutagenesis , NF-kappa B p50 Subunit/immunology , NF-kappa B p50 Subunit/metabolism , Peptide Fragments/genetics , Peptide Fragments/immunology , Peptide Fragments/therapeutic use , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Th1 Cells/immunology , Th1 Cells/metabolism
3.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-510513

ABSTRACT

This study aimed at investigating the inhibitory effects and the anti-tumor mechanisms of co-adminis-tration of fusion proteins mGM-CSF/βhCG ( GC ) and hVEGF121/βhCG ( VC ) on RM-1 prostatic cancer and B16 F10 melanoma in the C57 BL/6 J mouse model. Two recombinant stains containing pET-28 a-mGM-CSF-X10-βhCGCTP37 and pET-28 a-VEGF-M2-X10-βhCG-CTP37 were induced by lactose to express fusion proteins. The fusion proteins were separated and purified to prepare the anti-tumor protein vaccines ( VC protein vaccine and GC protein vaccine) , which were then mixed to prepare a combined protein vaccine named VGC protein vac-cine. The prostatic cancer and melanoma tumor-bearing mice C57 BL/6 J were immunized with described vac-cines, then the growth of each tumor was measured;splenocyte proliferation of immunized mice was detected;and the cytotoxic effects of the vaccine on tumor cells were tested. After that, the in vivo concentrations of IFN-γ and anti-hVEGF antibodies were investigated by ELISA. The difference between each experimental group and normal saline group ( NS) was statistically significant in both tumor-bearing mouse models ( P <0. 05) respectively. Besides, VGC group exhibited significantly better anti-tumor effect compared with the GC and VC groups with the anti-tumor rate ( 41. 7 ± 0. 83)% and ( 46. 4 ± 1. 27)% for prostatic cancer and melanoma tumor, respectively. The co-administration of the two proteins, VC and GC, could inhibit the growth of RM-1 prostatic tumor and B16F10 melanoma effectively via anti-tumor immunity and anti-tumor angiogenesis.

4.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-811893

ABSTRACT

@#Autophagosomes derived from tumor cells have been proved to induce potent T cell response both in mouse and human. In human in vitro study, dendritic cells(DC)loaded with cytomegalovirus(CMV)pp65 antigen-containing DRibble were capable to efficiently re-stimulate pp65-specific T-cell recall responses from freshly isolated or frozen humanperipheral blood mononuclear cell(PBMC). This study developed more robust assays using in vitro expanded antigen-specific T cells that contained a much higher percentage of antigen-specific T cells. DC cross-presentation efficiency of OX40 and CD80 modified pp65-DRibble was detected by intracellular IFN-γ staining. Compared with Ctrl/pp65 DRibble, the percentage of IFN-γ+ in total CD8+ T cells andCD4+ T cells was improvedwith OX40/pp65 DRibbleand CD80/pp65 DRibble stimulation. In addition, vaccine induced IL-12indendritic cells, whichpolarizes Th cells toward the IFN-γ high Th1 phenotype, evaluated by ELISA inco-culture supernatantwas dramatically higher in OX40/pp65 DRibble and CD80/pp65 DRibblegroups than in Ctrl/pp65 DRibble group. These results have implications for the immuneactivity of OX40 and CD80 modified DRibble and choice for prospective clinical use ofDRibble-based cancer immunotherapy.

5.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-811831

ABSTRACT

@#To investigate the effects of Mycobacterium tuberculosis heat shock protein 65(HSP65)on Treg/Th17 immune balance in ApoE-knockout(ApoE-/-)mice, ApoE-/- mice with a high-cholesterol diet were immunized with M. tuberculosis HSP65. Sera were obtained for measurement of anti-HSP65 antibodies by ELISA; the effect of administration of different antigens was investigated, respectively, using flow cytometry analysis on the number of CD4+CD25+Foxp3+Tregs and CD4+IL-17+ Th17; the production of cytokines(IL-10, TGF-β1, IL-17 and IL-21)by these cells were determined by ELISA; total plasma cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C)and low-density lipoprotein cholesterol(LDL-C)levels were detected by biochemical autoanalyzer. Atherosclerotic lesions were measured by lipid deposition stained with oil red O. The results demonstrated that the levels of anti-HSP65 IgG antibodies were increased significantly in Mycobacterium tuberculosis HSP65-treated ApoE-/- mice, revealed obvious decrease in Treg number, Treg related cytokines(IL-10, TGF-β1)levels and significant increase in Th17 number, Th17 related cytokines(IL-17 and IL-21)levels, the levels of TC, TG, HDL-C and LDL-C did not change between groups, while the atherosclerotic lesions significantly increased. Results indicate that M. tuberculosis HSP65 could interrupt the Th17/Treg immune balance in ApoE-/- mice, suggesting a potential role in the formation and progression of atherosclerosis.

6.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-811921

ABSTRACT

@#An expression vector pET-28a-mGM-CSF-X10-βhCGCTP37 plasmid containing the βhCG and mGM-CSF gene was designed and constructed. The fusion protein was induced by lactose and purified by ammonium sulfate precipitation and DEAE-cellulose anion exchange column. Then dendritic cells(DC)in C57BL/6J mice were extracted and sensitized by the fusion protein to obtain DC vaccine. The DC vaccine was inoculated to C57BL of / 6J mice with prostate cancer RM-1. The results indicated that the anti-tumor effects of DC group and DC combined with paclitaxel(DP)group were superior to that of paclitaxel(Pac)group(P< 0. 01), and the anti-tumor effect of DP group was better than that of DC group. Thus, the constructed DC vaccine can inhibit the growth of prostate cancer, and have synergistic anti-tumor when used with paclitaxel.

7.
Vaccine ; 30(6): 1029-37, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22192848

ABSTRACT

Previous investigations have demonstrated that anti-inflammatory or lipid-lowering treatments could be useful for alleviating morbidity and mortality of atherosclerotic cardiovascular diseases. However, whether a vaccine designed to target inflammation and lipid simultaneously is more powerful to control the process of atherosclerosis remain to be unknown. Here, a vaccine was designed to target heat shock protein-65(Hsp65) and cholesteryl ester transfer protein (CETP) simultaneously and the effects of nasal immunization of multi-target vaccine on high-cholesterol-diet-driven rabbit atherosclerosis lesions were evaluated. Sera, nasal lavages and lung washes were used to ELISA assay for the analysis of IgG and IgA against Hsp65 and CETP. Sera were also used to the analysis of the avidity of combination of anti-Hsp65 and anti-CETP IgG antibodies with corresponding antigen, cytokines IL-10 and IFN-γ, and lipoproteins. In addition, aortas were harvested for analysis of atherosclerotic lesions. The results showed that lower and lasting specific anti-Hsp65 IgG and high anti-CETP IgG in sera and protective anti-Hsp65 and anti-CETP IgA in nasal cavity and lung were induced, the avidity of combination of anti-Hsp65 and anti-CETP IgG with antigen were higher, and more protective IL-10 and less adverse IFN-γ were produced. In addition, sera TC, and LDL-C were decreased. As a result, the size of aorta atherosclerotic plaques was significantly reduced. We conclude that multifaceted vaccine combining lipid-regulating with anti-inflammation was a potential remedy, especially for atherosclerosis with complicated etiology.


Subject(s)
Atherosclerosis/prevention & control , Immunization/methods , Vaccines/administration & dosage , Vaccines/immunology , Administration, Intranasal , Animals , Aorta/pathology , Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Diet , Disease Models, Animal , Heat-Shock Proteins/antagonists & inhibitors , Immunoglobulin A/analysis , Immunoglobulin A/blood , Immunoglobulin G/analysis , Immunoglobulin G/blood , Lung/immunology , Male , Nasal Mucosa/immunology , Rabbits
8.
Vaccine ; 29(24): 4102-9, 2011 May 31.
Article in English | MEDLINE | ID: mdl-21497632

ABSTRACT

Lactococcus is a genus of Gram positive food-grade bacteria that has been widely used as a vaccine platform for the safe delivery of heterologous antigens. Many reports support the involvement of inflammation and immunity in atherosclerosis as well as the role of autoimmunity to heat shock proteins (HSPs) in the progression of atherogenesis. In this study, experiments were specifically designed to investigate the effect of oral administration of mycobacterial heat shock protein 65 (HSP65) delivered by Lactococcus lactis (L. lactis) on atherogenesis. Two types of HSP65-encoding plasmids for intracellular expression or secretion were constructed, and then transformed into L. lactis NZ9000. Oral administration of two recombinant L. lactis strains both induced suppression of HSP65-specific proliferation, accompanied by elevation of Interleukin-10 (IL-10) production and reduction of interferon-gamma (IFN-γ) level. Inducible HSP65-specific tolerance exerted a protective effect on atherosclerotic lesion formation and endothelial damage in low-density lipoprotein receptor-deficient (LDL-RD) mice model, while no obvious pathological abnormalities were observed. In conclusion, delivery of HSP65 at the intestinal mucosa by recombinant L. lactis provides a novel approach for the prevention of atherosclerosis. The results further illustrate the potential of using genetically modified L. lactis as a safe and effective vaccine delivery to elicit antigen-specific tolerance for treatment of autoimmune diseases.


Subject(s)
Atherosclerosis/prevention & control , Bacterial Proteins/immunology , Chaperonin 60/immunology , Receptors, LDL/deficiency , Tuberculosis Vaccines/immunology , Administration, Oral , Animals , Autoimmune Diseases/therapy , Bacterial Proteins/genetics , Chaperonin 60/genetics , Disease Models, Animal , Drug Carriers/administration & dosage , Genetic Vectors , Immune Tolerance , Lactococcus lactis/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Tuberculosis Vaccines/administration & dosage , Tuberculosis Vaccines/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology
9.
Braz. j. med. biol. res ; 44(2): 140-148, Feb. 2011. ilus
Article in English | LILACS | ID: lil-573650

ABSTRACT

Vaccination with xenogeneic and syngeneic endothelial cells is effective for inhibiting tumor growth. Nontoxic diphtheria toxin (CRM197), as an immunogen or as a specific inhibitor of heparin-binding EGF-like growth factor, has shown promising antitumor activity. Therefore, immunization with or administration of viable human umbilical vein endothelial cells (HUVECs) combined with CRM197 could have an enhanced antitumor effect. Six-week-old C57BL/6J male mice were vaccinated with viable HUVECs, 1 x 10(6) viable HUVECs combined with 100 μg CRM197, or 100 μg CRM197 alone by ip injections once a week for 4 consecutive weeks. RM-1 cells (5 x 10(5)) were inoculated by sc injection as a preventive procedure. During the therapeutic procedure, 6-week-old male C57BL/6J mice were challenged with 1 x 10(5) RM-1 cells, then injected sc with 1 x 10(6) viable HUVECs, 1 x 10(6) viable HUVECs + 100 μg CRM197, and 100 μg CRM197 alone twice a week for 4 consecutive weeks. Tumor volume and life span were monitored. We also investigated the effects of immunization with HUVECs on the aortic arch wall and on wound healing. Vaccination with or administration of viable HUVECs+CRM197 enhanced the inhibition of RM-1 prostatic carcinoma by 24 and 29 percent, respectively, and prolonged the life span for 3 and 4 days, respectively, compared with those of only vaccination or administration with viable HUVECs of tumor-bearing C57BL/6J mice. Furthermore, HUVEC immunization caused some damage to the aortic arch wall but did not have remarkable effects on the rate of wound healing; the wounds healed in approximately 13 days. Treatment with CRM197 in combination with viable HUVECs resulted in a marked enhancement of the antitumor effect in the preventive or therapeutic treatment for prostatic carcinoma in vivo, suggesting a novel combination for anti-cancer therapy.


Subject(s)
Animals , Humans , Male , Mice , Bacterial Proteins/therapeutic use , Human Umbilical Vein Endothelial Cells/transplantation , Prostatic Neoplasms/therapy , Bacterial Proteins/immunology , Combined Modality Therapy/methods , Human Umbilical Vein Endothelial Cells/immunology , Prostatic Neoplasms/immunology , Transplantation, Heterologous , Transplantation, Isogeneic , Xenograft Model Antitumor Assays
10.
Braz J Med Biol Res ; 44(2): 140-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21180889

ABSTRACT

Vaccination with xenogeneic and syngeneic endothelial cells is effective for inhibiting tumor growth. Nontoxic diphtheria toxin (CRM197), as an immunogen or as a specific inhibitor of heparin-binding EGF-like growth factor, has shown promising antitumor activity. Therefore, immunization with or administration of viable human umbilical vein endothelial cells (HUVECs) combined with CRM197 could have an enhanced antitumor effect. Six-week-old C57BL/6J male mice were vaccinated with viable HUVECs, 1 x 10(6) viable HUVECs combined with 100 µg CRM197, or 100 µg CRM197 alone by ip injections once a week for 4 consecutive weeks. RM-1 cells (5 x 10(5)) were inoculated by sc injection as a preventive procedure. During the therapeutic procedure, 6-week-old male C57BL/6J mice were challenged with 1 x 10(5) RM-1 cells, then injected sc with 1 x 10(6) viable HUVECs, 1 x 10(6) viable HUVECs + 100 µg CRM197, and 100 µg CRM197 alone twice a week for 4 consecutive weeks. Tumor volume and life span were monitored. We also investigated the effects of immunization with HUVECs on the aortic arch wall and on wound healing. Vaccination with or administration of viable HUVECs+CRM197 enhanced the inhibition of RM-1 prostatic carcinoma by 24 and 29%, respectively, and prolonged the life span for 3 and 4 days, respectively, compared with those of only vaccination or administration with viable HUVECs of tumor-bearing C57BL/6J mice. Furthermore, HUVEC immunization caused some damage to the aortic arch wall but did not have remarkable effects on the rate of wound healing; the wounds healed in approximately 13 days. Treatment with CRM197 in combination with viable HUVECs resulted in a marked enhancement of the antitumor effect in the preventive or therapeutic treatment for prostatic carcinoma in vivo, suggesting a novel combination for anti-cancer therapy.


Subject(s)
Bacterial Proteins/therapeutic use , Human Umbilical Vein Endothelial Cells/transplantation , Prostatic Neoplasms/therapy , Animals , Bacterial Proteins/immunology , Combined Modality Therapy/methods , Human Umbilical Vein Endothelial Cells/immunology , Humans , Male , Mice , Mice, Inbred C57BL , Prostatic Neoplasms/immunology , Transplantation, Heterologous , Transplantation, Isogeneic , Xenograft Model Antitumor Assays
11.
Gene Ther ; 17(4): 459-68, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20130655

ABSTRACT

Gastrin-releasing peptide (GRP), a bombesin-like peptide, is an autocrine or paracrine growth factor that can stimulate the growth of various cancer cells, making it an ideal target antigen to develop vaccines against cancer. In this study, we developed a novel DNA vaccine that encodes six tandem repeats of B-cell epitope GRP(18-27) (GRP6) flanked by HSP65 as carrier and four tandem repeats of mycobacterial HSP70(407-426) (M4) as helper T-cell epitopes for enhancement of immunogenicity. When intramuscularly immunized to mice, this anti-GRP DNA vaccine-induced GRP-specific antibody (Ab) responses that were at least 10-fold higher in magnitude compared with HSP65-GRP6 protein vaccine. Both prophylactic and therapeutic antitumor immunities induced by vaccination significantly suppressed the growth of GRP-dependent prostate carcinoma RM-1 in vivo and prolonged the survival of tumor-inoculated mice. Out results also showed that the immune sera with high titer of GRP-specific Abs effectively inhibited the growth of tumor in mice and dose dependently inhibited proliferation of cultured RM-1 cells in vitro, suggesting that the GRP neutralizing Ab is responsible for the protective and therapeutic antitumor activity of vaccination. These findings may be of great importance in the further exploration of the applications of growth factors identified in human in cancer therapy.


Subject(s)
Cancer Vaccines/immunology , Carcinoma/prevention & control , Epitopes, B-Lymphocyte/immunology , Gastrin-Releasing Peptide/immunology , Prostatic Neoplasms/prevention & control , Vaccines, DNA/immunology , Animals , Cancer Vaccines/pharmacology , Carcinoma/immunology , Cell Line, Tumor , Cell Proliferation/drug effects , Epitopes, B-Lymphocyte/genetics , HSP70 Heat-Shock Proteins/genetics , HSP70 Heat-Shock Proteins/immunology , Immunohistochemistry , Male , Mice , Prostatic Neoplasms/immunology , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/pharmacology , Vaccines, DNA/pharmacology
12.
Int Immunopharmacol ; 10(2): 230-8, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19913113

ABSTRACT

It has been demonstrated that the beta-subunit of human chorionic gonadotropin (beta-hCG) is ectopically expressed on a variety of human cancers of different histological types and has been used as an antigenic target in anti-cancer vaccines. We engineered a fusion protein by fusing 10 tandemly repeated copies of the 10-residue sequence of beta-hCG (109-118) (in CTP37) combined with beta-hCG C-terminal 37 peptides to mycobacterial heat-shock protein 65 and immunized mice via subcutaneous injection. Humoral immune and cellular immune responses were effectively elicited. High titer of anti-beta-hCG antibody was detected in immunized mice sera by ELISA and verified by Western blot analyses. The fusion protein of HSP65-X10-beta-hCGCTP37 effectively inhibited the growth of tumor both protective and therapeutic anti-tumor immunity in hepatocellular carcinoma tumor models in mice. Meanwhile, it also attenuated tumor-induced angiogenesis in intradermal tumor model in mice. Taken together, these results demonstrate that immune responses are effectively induced by a novel fusion protein vaccine targeting beta-hCG, suppressing the growth of hepatocellular carcinoma in mice. The beta-hCG-targeted vaccine holds promise for the treatment of a number of cancers and merits further study.


Subject(s)
Bacterial Proteins/immunology , Cancer Vaccines/immunology , Carcinoma, Hepatocellular/therapy , Chaperonin 60/immunology , Chorionic Gonadotropin, beta Subunit, Human/immunology , Liver Neoplasms/therapy , Recombinant Fusion Proteins/immunology , Animals , Antibodies, Neoplasm/immunology , Antibody Specificity/immunology , Bacterial Proteins/genetics , Bacterial Proteins/therapeutic use , Cancer Vaccines/genetics , Cancer Vaccines/therapeutic use , Carcinoma, Hepatocellular/immunology , Chaperonin 60/genetics , Chaperonin 60/therapeutic use , Chorionic Gonadotropin, beta Subunit, Human/genetics , Chorionic Gonadotropin, beta Subunit, Human/therapeutic use , Liver Neoplasms/immunology , Male , Mice , Neovascularization, Pathologic/immunology , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/therapeutic use , Tandem Repeat Sequences
13.
Regul Pept ; 157(1-3): 92-8, 2009 Oct 09.
Article in English | MEDLINE | ID: mdl-19523989

ABSTRACT

A novel insulin analog, PIns, with N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at human regular insulin B-chain was acquired through gene engineering. Preproinsulin for PIns was cloned and expressed using a bacterial expression system at a high level (72.1%) as fusion protein carrying a modified thioredoxin N-terminal region (1-21) linked to N-terminus of proinsulin by a lysine residue. Purified fusion protein was refolded and converted into PIns by a single enzymatic reaction. After PIns was purified, the homogeneity of it was characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis, isoelectronic focusing electrophoresis, amino acid composition analysis and mass spectrometry methods. A decreased tendency of self-association of PIns as compared with regular insulin was demonstrated by the size exclusion HPLC analysis. When subcutaneously administrated into normal rats, the PIns showed a faster rate of onset of action and a shorter duration of action compared with regular insulin, similar to the pharmacokinetic characteristics of insulin Lispro. These results showed that PIns is a rapid insulin analog. Furthermore, the N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at insulin B-chain can be excised by DPPIV and recombinant peptidase with DPPIV-like activities. It is suggested that PIns serves as an artificial insulin precursor and can be transformed to regular insulin in vivo due to the truncation of N-terminal sequence of PIns B-chain by DPPIV.


Subject(s)
Insulin/analogs & derivatives , Insulin/biosynthesis , Insulin/pharmacokinetics , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/pharmacokinetics , Animals , Genetic Engineering , Humans , Injections, Subcutaneous , Insulin/chemistry , Male , Rats , Rats, Wistar , Recombinant Fusion Proteins/chemistry
14.
Protein Pept Lett ; 15(7): 745-52, 2008.
Article in English | MEDLINE | ID: mdl-18782072

ABSTRACT

In order to prevent atherosclerosis, a chimeric enzyme vaccine of AnsB-TTP-PADRE-CETPC was successfully constructed, expressed and purified to immunize New Zealand white rabbits for inducing high titers of anti-CETP antibodies to improve lipid abnormality. The protein was expressed as soluble protein in Escherichia coli and purified by anion exchange column and Sephadex G-100 size-exclusion chromatography. After immunizing rabbits with the purified protein, high titer anti-CETP antibodies were induced and lasted more than nineteen weeks in vivo; High density lipoprotein cholesterol (HDL-C) content in the serum was elevated to 61% while decreased low density lipoprotein cholesterol (LDL-C) to 37.2% compared with control rabbits in the presence of Al(OH) (3).


Subject(s)
Atherosclerosis/immunology , Atherosclerosis/prevention & control , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Amino Acid Sequence , Animals , Antibody Formation , Asparaginase/genetics , Asparaginase/immunology , Atherosclerosis/blood , Base Sequence , Cholesterol Ester Transfer Proteins/genetics , Cholesterol Ester Transfer Proteins/immunology , DNA Primers/genetics , Epitopes, B-Lymphocyte/genetics , Epitopes, T-Lymphocyte/genetics , Escherichia coli/genetics , Humans , Lipids/blood , Malaria Vaccines/genetics , Malaria Vaccines/immunology , Male , Molecular Sequence Data , Peptide Fragments/genetics , Peptide Fragments/immunology , Rabbits , Tetanus Toxin/genetics , Tetanus Toxin/immunology , Vaccines, Synthetic/pharmacology
15.
Endocr Relat Cancer ; 15(1): 149-59, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18310283

ABSTRACT

Gastrin-releasing peptide (GRP), a bombesin-like peptide, is an autocrine growth factor that can stimulate the growth of various cancer cells. We developed a novel protein vaccine HSP65-(GRP-10)(6) (HG6) that consists of six copies of a 10-amino acid residue epitope of GRP C-terminal fragment carried by mycobacterial 65 kDa HSP65 and then immunized mice via subcutaneous injection. Strong humoral and cell-mediated immune responses were induced. High titer of anti-GRP antibodies was detected in immunized mice sera by ELISA and verified by Western blot analysis. Activity of CD4+T lymphocytes, especially high levels of interferon (INF)-gamma, were developed in mice immunized with HG6 when compared with HSP65 or PBS. We found that immunogene tumor therapy with a vaccine based on GRP was effective at both protective and therapeutic antitumor immunity in breast tumor models in mice. The purified GRP monoclonal antibody (McAb) was proved to be potential in inhibiting EMT-6 tumor cell proliferation in vitro. The attenuation induced by active immune responses on tumor-induced angiogenesis was observed with an intradermal tumor model in mice. Taken together, we demonstrate for the first time that immune responses that are elicited by a novel chimeric protein vaccine targeting GRP can suppress the proliferation of breast tumor cell EMT-6 in mice, and it may be of importance in the further exploration of the applications of other autocrine growth factor identified in human and other animal in cancer therapy.


Subject(s)
Bombesin/immunology , Breast Neoplasms/therapy , Cancer Vaccines/administration & dosage , Peptide Fragments/immunology , Animals , Antibodies, Monoclonal/immunology , Blotting, Western , Breast Neoplasms/immunology , Breast Neoplasms/pathology , CD4-Positive T-Lymphocytes/immunology , Cell Proliferation , DNA Primers , Enzyme-Linked Immunosorbent Assay , Immunization , Interferon-gamma/metabolism , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Neovascularization, Pathologic , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Xenograft Model Antitumor Assays
16.
Vaccine ; 24(23): 4942-50, 2006 Jun 05.
Article in English | MEDLINE | ID: mdl-16697088

ABSTRACT

Rabbits were intramuscularly immunized with the plasmid pCR-X8-HBc-CETP encoding a B-cell epitope of cholesteryl ester transfer protein (CETP) C-terminal fragment (CETPC) displayed by Hepatitis B virus core (HBc) particle. This plasmid also contained immunostimulatory sequences (ISS) which included eight CpG motifs 5'-GACGTT-3', functioning as immunomodulators. After anti-CETP antibodies were successfully produced, rabbits were fed with a high-cholesterol diet for 15 weeks, and then the antiatherogenic effects of this DNA immunization were evaluated. The results showed that the fraction of plasma cholesterol in HDL significantly increased and the fraction of plasma cholesterol in LDL decreased in the pCR-X8-HBc-CETP immunized rabbits compared with those in the saline control group and one group treated with the plasmid pCR-X8-HBc containing ISS but lacking CETP epitope. More importantly, DNA immunization with pCR-X8-HBc-CETP markedly reduced the average percentage of aortic lesions in the entire aorta area by 80.60% compared with the saline control (3.78% versus 19.48%) and the average thickness of hyperplastic coronary artery in this group was also significantly less than in the saline control group (146+/-11 microm versus 248+/-18 microm). Our data also showed that CpG DNA alone could be antiatherogenic in this model because the average percentage of aortic lesions in pCR-X8-HBc immunized rabbits was 16.53% lower than that of the saline control group and the average thickness of hyperplastic coronary artery was also substantially lower than saline control group (155+/-13 microm versus 248+/-18 microm). Thus, plasmid pCR-X8-HBc-CETP could significantly inhibit the progression of atherosclerosis and be potentially developed as a suitable DNA vaccine against atherosclerosis.


Subject(s)
Atherosclerosis/prevention & control , Carrier Proteins/immunology , CpG Islands/immunology , Epitopes/immunology , Glycoproteins/immunology , Hepatitis B Core Antigens/chemistry , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Animals , Antibodies/analysis , Antibodies/immunology , Aorta/pathology , Atherosclerosis/pathology , Carrier Proteins/genetics , Cholesterol/analysis , Cholesterol Ester Transfer Proteins , Coronary Vessels/pathology , CpG Islands/genetics , Epitopes/genetics , Genetic Vectors , Glycoproteins/genetics , Injections, Intramuscular , Kidney/immunology , Kidney/pathology , Lipoproteins/chemistry , Rabbits , Vaccines, DNA/genetics
17.
Biochem Biophys Res Commun ; 345(4): 1365-71, 2006 Jul 14.
Article in English | MEDLINE | ID: mdl-16725110

ABSTRACT

The beta-subunit of human chorionic gonadotropin (beta-hCG) is secreted by many kinds of tumors and it has been used as an ideal target antigen to develop vaccines against tumors. In view of the low immunogenicity of this self-peptide,we designed a method based on isocaudamer technique to repeat tandemly the 10-residue sequence X of beta-hCG (109-118), then 10 tandemly repeated copies of the 10-residue sequence combined with beta-hCG C-terminal 37 peptides were fused to mycobacterial heat-shock protein 65 to construct a fusion protein HSP65-X10-betahCGCTP37 as an immunogen. In this study, we examined the effect of the tandem repeats of this 10-residue sequence in eliciting an immune by comparing the immunogenicity and anti-tumor effects of the two immunogens, HSP65-X10-betahCGCTP37 and HSP65-betahCGCTP37 (without the 10 tandem repeats). Immunization of mice with the fusion protein HSP65-X10-betahCGCTP37 elicited much higher levels of specific anti-beta-hCG antibodies and more effectively inhibited the growth of Lewis lung carcinoma (LLC) in vivo than with HSP65-betahCGCTP37, which should suggest that HSP65-X10-betahCGCTP37 may be an effective protein vaccine for the treatment of beta-hCG-dependent tumors and multiple tandem repeats of a certain epitope are an efficient method to overcome the low immunogenicity of self-peptide antigens.


Subject(s)
Bacterial Proteins/immunology , Cancer Vaccines/immunology , Chaperonins/immunology , Chorionic Gonadotropin, beta Subunit, Human/genetics , Peptide Fragments/immunology , Repetitive Sequences, Amino Acid/genetics , Amino Acid Sequence , Animals , Antibody Specificity/immunology , Bacterial Proteins/genetics , Blotting, Western , Cancer Vaccines/genetics , Cancer Vaccines/therapeutic use , Carcinoma, Lewis Lung/immunology , Carcinoma, Lewis Lung/pathology , Carcinoma, Lewis Lung/prevention & control , Cell Line, Tumor , Chaperonin 60 , Chaperonins/genetics , Chorionic Gonadotropin, beta Subunit, Human/chemistry , Enzyme-Linked Immunosorbent Assay , Humans , Mice , Mice, Inbred C57BL , Peptide Fragments/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Time Factors , Treatment Outcome , Vaccination/methods
18.
Protein Pept Lett ; 13(2): 149-54, 2006.
Article in English | MEDLINE | ID: mdl-16472077

ABSTRACT

The recombinant chimeric enzyme, AnsB-TTP-CETPC, comprising asparaginase, tetanus toxin helper T cell epitope and human CETP B cell epitope was expressed as a soluble protein in Escherichia coli. The purified chimeric enzyme exhibited approximate 83% activity of the native asparaginase. After immunization with three doses of chimeric enzyme, high titers of anti-CETP antibodies were induced and lasted more than eighteen weeks in mice, and could even be detected at a dilution of 1:12800 by normal ELISA assay. The specificity of anti-CETP antibody was verified by Western blot assay. After displaying on the surface of asparaginase, the weak antigenicity of CETP epitope was effectively overcome, there after a strong CETP-specific immune response was evoked in mice immunized with the chimeric enzyme. Histochemical analysis of mice kidney tissue showed that immunization with the chimeric enzyme did not cause any pathological changes in mice. Collectively, the chimeric enzyme may be further developed as a vaccine against atherosclerosis in the future.


Subject(s)
Antibodies/blood , Antibodies/immunology , Asparaginase/metabolism , Carrier Proteins/immunology , Carrier Proteins/metabolism , Epitopes, B-Lymphocyte/immunology , Glycoproteins/immunology , Glycoproteins/metabolism , Amino Acid Sequence , Animals , Asparaginase/chemistry , Asparaginase/genetics , Carrier Proteins/chemistry , Carrier Proteins/genetics , Cholesterol Ester Transfer Proteins , Gene Expression , Glycoproteins/chemistry , Glycoproteins/genetics , Humans , Kidney/immunology , Kidney/metabolism , Mice , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism , Titrimetry
19.
Vaccine ; 24(14): 2575-84, 2006 Mar 24.
Article in English | MEDLINE | ID: mdl-16420967

ABSTRACT

Studies have demonstrated that active-specific immunotherapy has potential for controlling mammary tumor progression. Human chorionic gonadotropin (hCG) is expressed and extremely sensitive, easily detectable and highly correlated with breast cancer. We developed a gene vaccine using a plasmid vector to deliver the six copies of 10-amino acid residues of beta-hCG 109-118 and beta hCG C-terminal 37-amino acid (CTP37). BALB/c female mice were immunized with a combination of pCR-HBc-X6-betahCGCTP37 DNA vaccine and HSP-X6-betahCGCTP37 protein vaccine. pCR-HBc-X6-betahCGCTP37 DNA vaccine were injected intramuscularly three times, on days -46,-25 and -11 and HSP-X6-betahCGCTP37 protein were applied two times, 21 and 14 days before tumor cell challenge. We assessed a combined DNA and protein vaccine for its effect of against murine EMT6 mammary tumor cells. In this study, animals vaccinated DNA vaccination boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65 induced higher avidity antibodies and effectively inhibited the growth of tumor, compared with treatment using DNA alone or BCG priming HSP-X6-betahCGCTP37 protein boosting. The data presented demonstrate that improve immunogenicity of DNA vaccination by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65, which should prove useful in the development of new DNA vaccine against growth factors for cancer immunotherapy.


Subject(s)
Bacterial Proteins/chemistry , Breast Neoplasms/therapy , Cancer Vaccines/therapeutic use , Chaperonins/chemistry , Chorionic Gonadotropin/administration & dosage , Vaccines, DNA/administration & dosage , Animals , Antibodies, Neoplasm/blood , Breast Neoplasms/immunology , Carrier Proteins/administration & dosage , Carrier Proteins/chemistry , Cell Line, Tumor , Chaperonin 60 , Chorionic Gonadotropin/chemistry , Humans , Immunotherapy , Mice , Mycobacterium/chemistry , Protein Structure, Tertiary , Repetitive Sequences, Nucleic Acid , Vaccination/methods , Vaccination/standards , Vaccines, DNA/immunology
20.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-434064

ABSTRACT

Aim:To obtain recombinant human proinsulin C-peptide,a novel expression vector pEDCC was constructed to facilitate the expression and purification of C-peptide. Methods:Gene fragments encoding a truncated asparaginase fragment mutant,native C-peptide,a hinge fragment of human IgG1,an extra acid-labile dipeptide and a basic-amino-acid-riched octopeptide were introduced in turn into plasmid pET28a. The fusion protein ansB-C-hinge-DPKRKRKKSRNGSGR-C-peptide was expressed effectively as inclusion bodies after induced by lactose and partially purified by means of washing and ethanol fractionation. After being hydrolyzed,the polypeptide PKRKRKKSRNGSGR-C-peptide was liberated from the fusion partner. The N-terminal tetradecapeptide extension of C-peptide was subsequently cleaved by trypsin and removed by DE52 column. Results:The nucleotides sequence of plasmid pEDCC was confirmed to be identical with that of designed fusion protein. Recombinant human proinsulin C-peptide was obtained with high purity after purification. Conclusion:Employing truncated asparaginase as the fusion partner and basic-amino-acid-riched octopeptide to modulate isoelectric point is an effective approach to produce recombinant human proinsulin C-peptide.

SELECTION OF CITATIONS
SEARCH DETAIL
...